• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Joseph Vassalotti on How Risk Stratification Informed a Primary Care CKD Intervention

Video

Population health screening involves risk stratification that allows interventions to be targeted to appropriate patients, as was demonstrated in a study of a chronic kidney disease (CKD) intervention published in the November issue of The American Journal of Managed Care®, said lead author Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.

Population health screening involves risk stratification that allows interventions to be targeted to appropriate patients, as was demonstrated in a study of a chronic kidney disease (CKD) intervention published in the November issue of The American Journal of Managed Care®, said lead author Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.

Transcript

What is the importance of CKD screening and detection for population health?

One of the most important things for population health screening is to not only stratify the risk, but also stratify the interventions accordingly. We stratified the interventions including things like risk factor control for diabetes, medical nutrition therapy for diabetes and hypertension, pharmacist evaluation for drug safety interactions, dose adjustment for reduced kidney function, and nephrology consultation for advanced disease, as well as preparation for kidney replacement therapy. All of those were incorporated in a stepwise fashion into the patient-centered medical home population. There was an incentive for the primary care clinician that was upside only to meet cost containment, to meet some quality improvement measures that included both diabetes and hypertension management as well as kidney disease management.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.